Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
Regeneron Pharmaceuticals, Inc. (REGN) had Free Cash Flow per Share of $7.88 for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$3.61B |
|
$727.20M |
|
$669.40M |
|
$2.94B |
|
$2.96B |
|
$642.90M |
|
$188.30M |
|
$831.20M |
|
$831.20M |
|
$727.20M |
|
$727.20M |
|
$727.20M |
|
$727.20M |
|
$642.90M |
|
$766.10M |
|
104.00M |
|
107.70M |
|
$6.99 |
|
$6.75 |
|
| Balance Sheet Financials | |
$18.21B |
|
$5.27B |
|
$22.66B |
|
$40.87B |
|
$5.11B |
|
$1.99B |
|
$4.34B |
|
$9.45B |
|
$31.42B |
|
$30.14B |
|
$31.42B |
|
105.00M |
|
| Cash Flow Statement Financials | |
$1.08B |
|
$-428.90M |
|
$-802.20M |
|
$3.12B |
|
$2.97B |
|
$-153.10M |
|
$257.40M |
|
$-97.80M |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.56 |
|
-- |
|
-- |
|
0.06 |
|
0.09 |
|
81.43% |
|
17.83% |
|
17.83% |
|
-- |
|
23.05% |
|
20.17% |
|
$848.30M |
|
-- |
|
-- |
|
-- |
|
0.09 |
|
0.22 |
|
0.63 |
|
143.06 |
|
2.31% |
|
2.41% |
|
1.78% |
|
2.18% |
|
$299.27 |
|
|
Free Cash Flow per Share |
$7.88 |
$10.02 |
|